Monographie - Amsacrine - Stabilis 4.0

Siste oppdatering :
19/11/2024

kreft narkotika

Amsacrine

Injeksjon

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Kjemisk struktur

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Amekrin	Danmark, Finland, Norge, Sverige
Amsa PD	Canada
Amsalyo	Frankrike
Amsidine	Australia, Belgia, Italia, Nederland
Amsidyl	Sveits, Tyskland

Referanser

Injeksjon

Referanser : Amsacrine

	Type	publikasjon
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
253	Journal	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
829	Journal	Cartwright-Shamoon JM, McElnay JC, D'Arcy PF. Examination of sorption and photodegradation of amsacrine during storage in intravenous burette administration sets. Int J Pharm 1988 ; 42: 41-46.
3523	Labratorium	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3576	Labratorium	Amsacrine (Amsalyo®) - Résumé des caractéristiques du produit Prostrakan 2012
3595	Labratorium	Aciclovir - Summary of Product Characteristics Hospira 2009
3745	Journal	Kuenhle C, Moore Sodium chloride residue provides potential for drug incompatibiities. Am J Hosp Pharm 1979 ; 36: 881.

Mentions Légales